← Back to Search

National Cancer Institute "Cancer Moonshot Biobank"

N/A

Recruiting

Led By Helen M Moore

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 10 years

Awards & highlights

No Placebo-Only Group

Summary

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Eligible Conditions

Lung Cancer
Gastric cancer
Esophageal cancer
Colorectal Cancer
Multiple Myeloma
Breast cancer
Breast Cancer
Prostate Cancer
Ovarian Cancer
Cancer
Esophageal Carcinoma
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Acute Myeloid Leukemia
Cutaneous Melanoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percentage of enrolled patients by cancer type and treatment regimen overall

Procure, store and distribute longitudinal biospecimens and associated clinical data

Secondary study objectives

Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution

Pan-cancer gene panel tumor next generation sequencing test

Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository

+4 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Ancillary-correlative (biospecimen collection, chart review)Experimental Treatment2 Interventions

Patients undergo collection of tissue and blood samples prior to initiation of treatment, during treatment, post treatment and at disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected, if available. Patient medical records are reviewed, and data is collected for at least 5 years.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Biospecimen Collection

2004

Completed Phase 3

~2030

Do I qualify?Apply below to find out